Development Of A High-Dose Engineered Tcr T Cell Manufacturing Process Using Automated Semi-Continuous Perfusion Bioreactors

Conference Dates

January 15-19, 2017


Clinical activity with engineered TCR (eTCR) T cell products directed against solid tumor indications may require doses up to two orders of magnitude greater than those investigated during CAR-T studies in hematological malignancies.1 Novel methods for optimizing productivity and production times are required to progress the industrial feasibility of high-dose cell therapies. We developed an automated semi-continuous perfusion culture method suitable for rapidly generating high T cell densities with the aid of risk-based process models. The result is a robust manufacturing process capable of generating a target dose with high certainty, and minimal operational complexity and variability.

Please click Additional Files below to see the full abstract.

This document is currently not available here.